A number of other analysts also recently weighed in on the company. HC Wainwright increased their price objective on Urovant Sciences from $28.00 to $33.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. Zacks Investment Research downgraded Urovant Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Urovant Sciences has an average rating of “Buy” and a consensus price target of $22.69.
NASDAQ UROV traded down $0.14 on Tuesday, reaching $12.85. The company had a trading volume of 868 shares, compared to its average volume of 62,889. The firm has a market cap of $392.92 million, a price-to-earnings ratio of -3.03 and a beta of 1.97. Urovant Sciences has a fifty-two week low of $6.45 and a fifty-two week high of $15.98. The business has a 50 day moving average of $13.26 and a two-hundred day moving average of $10.09. The company has a debt-to-equity ratio of 1.83, a current ratio of 6.65 and a quick ratio of 6.65.
A number of institutional investors have recently modified their holdings of UROV. Marshall Wace LLP acquired a new stake in Urovant Sciences during the 1st quarter worth about $325,000. Marshall Wace North America L.P. acquired a new stake in Urovant Sciences during the 1st quarter worth about $49,000. FMR LLC grew its holdings in Urovant Sciences by 28.4% during the 1st quarter. FMR LLC now owns 1,710,836 shares of the company’s stock worth $17,194,000 after acquiring an additional 378,135 shares during the period. Northern Trust Corp grew its stake in shares of Urovant Sciences by 55.8% in the 2nd quarter. Northern Trust Corp now owns 17,164 shares of the company’s stock valued at $136,000 after buying an additional 6,144 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Urovant Sciences by 7.3% in the 2nd quarter. Vanguard Group Inc. now owns 131,487 shares of the company’s stock valued at $1,040,000 after buying an additional 9,000 shares during the period. Hedge funds and other institutional investors own 22.37% of the company’s stock.
Urovant Sciences Company Profile
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Featured Article: What does the Dogs of the Dow mean?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.